Summary
Edwards Lifesciences Corporation (EW) reported strong top-line growth in the second quarter and first half of 2016, driven primarily by its Transcatheter Heart Valve Therapy (THVT) segment, particularly the SAPIEN 3 valve. Net sales increased by 23.1% year-over-year for the quarter and 20.7% for the first half, with the United States showing a robust 32.6% growth in both periods. While revenue performance was strong, gross profit margin saw a decline due to foreign currency exchange rate fluctuations and other factors, though partially offset by a favorable product mix. The company also incurred a significant $34.5 million in-process research and development (IPR&D) charge related to acquired technologies for its transcatheter heart valve programs. Despite this, net income saw a healthy increase, reflecting the strong sales performance. The company continues to invest heavily in R&D, with a focus on new mitral and aortic THVT product development. Significant ongoing litigation with Boston Scientific remains a key point to monitor, although management believes it will not materially impact the company's financial position or liquidity.
Financial Highlights
49 data points| Revenue | $759.30M |
| Cost of Revenue | $202.50M |
| Gross Profit | $556.80M |
| R&D Expenses | $112.50M |
| SG&A Expenses | $228.80M |
| Interest Expense | $2.40M |
| Net Income | $126.60M |
| EPS (Basic) | $0.20 |
| EPS (Diluted) | $0.19 |
| Shares Outstanding (Basic) | 636.60M |
| Shares Outstanding (Diluted) | 651.90M |
Key Highlights
- 1Net sales increased by 23.1% to $759.3 million in Q2 2016 and by 20.7% to $1,456.6 million in the first six months of 2016, driven by strong performance in Transcatheter Heart Valve Therapy (THVT).
- 2The THVT segment saw a 48.7% increase in Q2 net sales and a 43.0% increase in the first six months, largely attributed to the successful launch and adoption of the Edwards SAPIEN 3 valve in the US and Europe.
- 3The United States market showed particularly strong growth, with net sales up 32.6% in both the quarter and the first half of 2016.
- 4Gross profit margin decreased as a percentage of net sales in the first half of 2016, primarily due to foreign currency exchange rate fluctuations, though partially offset by an improved product mix from THVT.
- 5The company recorded a $34.5 million charge for in-process research and development (IPR&D) related to acquired technologies for its transcatheter heart valve programs in May 2016.
- 6Net income increased to $126.6 million in Q2 2016 and $269.6 million in the first six months, demonstrating improved profitability despite R&D investments and IPR&D charges.
- 7Significant intellectual property litigation with Boston Scientific is ongoing, with trials scheduled in early 2017 for multiple cases in Germany, France, and the US.